The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Sacubitril/valsartan: implementation in primary care

Sacubitril/valsartan: implementation in primary care

Publication date: Friday, 21 October 2016
Contributor(s): Chris Arden

This article describes the use of sacubitril/valsartan – the first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) in primary care and how the new drug fits in the heart failure treatment pathway. Current guidelines and case studies are also explored to provide further understanding of this latest HF treatment to enter clinical use.

Sponsorship information:
This sponsored supplement was initiated and funded by Novartis. Novartis reviewed the supplement for technical accuracy and suitability within the ABPI Code of Practice. Final editorial control rests with the authors and editors.
Topics covered:
Category: Editorial
Edition: Volume 9 Number 1 Oct-Nov-Dec 2016
Contributor(s): Chris Arden

Article search and filter